AR072561A1 - Complejo de inclusion de clorhidrato de raloxifeno y b- ciclodextrina - Google Patents

Complejo de inclusion de clorhidrato de raloxifeno y b- ciclodextrina

Info

Publication number
AR072561A1
AR072561A1 ARP090102669A ARP090102669A AR072561A1 AR 072561 A1 AR072561 A1 AR 072561A1 AR P090102669 A ARP090102669 A AR P090102669A AR P090102669 A ARP090102669 A AR P090102669A AR 072561 A1 AR072561 A1 AR 072561A1
Authority
AR
Argentina
Prior art keywords
inclusion complex
raloxifen
chlorhydrate
cyclodextrine
complex inclusion
Prior art date
Application number
ARP090102669A
Other languages
English (en)
Inventor
Massimo Ferrari
Pietro Carlo Gargani
Original Assignee
Erregierre Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erregierre Spa filed Critical Erregierre Spa
Publication of AR072561A1 publication Critical patent/AR072561A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe un complejo de inclusion de clorhidrato de raloxifeno y beta-ciclodextrina en la fase solida, que tiene un espectro de difraccion de rayos X de polvo. A su vez, la solicitud se relaciona a un proceso de obtencion del complejo de inclusion de clorhidrato de raloxifeno y beta-ciclodextrina de la presente solicitud. El complejo de inclusion se emplea como producto farmacéutico en el tratamiento de la osteoporosis y específicamente en la osteoporosis postmenopáusica. Reivindicacion 4: El complejo de inclusion segun cualquiera de las reivindicaciones 1 a 3, caracterizado porque comprende 57 picos en los siguientes grados de difraccion e intensidad relativa, segun se muestra en la tabla (1).
ARP090102669A 2009-05-21 2009-07-14 Complejo de inclusion de clorhidrato de raloxifeno y b- ciclodextrina AR072561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09425196A EP2253627A1 (en) 2009-05-21 2009-05-21 Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.

Publications (1)

Publication Number Publication Date
AR072561A1 true AR072561A1 (es) 2010-09-08

Family

ID=41011803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102669A AR072561A1 (es) 2009-05-21 2009-07-14 Complejo de inclusion de clorhidrato de raloxifeno y b- ciclodextrina

Country Status (15)

Country Link
US (1) US20100298265A1 (es)
EP (1) EP2253627A1 (es)
JP (1) JP2010270100A (es)
KR (1) KR20100126146A (es)
CN (1) CN101890171A (es)
AR (1) AR072561A1 (es)
AU (1) AU2009202887A1 (es)
BR (1) BRPI0902387A2 (es)
CA (1) CA2671921A1 (es)
IL (1) IL199883A0 (es)
MX (1) MX2009007785A (es)
NZ (1) NZ578451A (es)
RU (1) RU2009127394A (es)
TW (1) TW201041878A (es)
ZA (1) ZA200905145B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198274B (zh) * 2011-03-30 2013-04-24 天津红日药业股份有限公司 雷洛昔芬的环糊精包合物及其制剂的制备方法
ITMI20121821A1 (it) * 2012-10-25 2014-04-26 Erregierre Spa Composizione farmaceutica solubile in acqua a base di un sale di raloxifene
KR102583356B1 (ko) * 2017-01-09 2023-09-26 에스씨아이팜 에스에이알엘 수용성 포스콜린의 신규 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135176C1 (ru) 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
US6713494B1 (en) * 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
CN1210079C (zh) * 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
US20060105045A1 (en) 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
EP2271320A4 (en) * 2008-04-02 2011-05-18 Reddys Lab Ltd Dr PHARMACEUTICAL RALOXIFY FORMULATIONS

Also Published As

Publication number Publication date
US20100298265A1 (en) 2010-11-25
MX2009007785A (es) 2010-11-22
NZ578451A (en) 2010-09-30
CA2671921A1 (en) 2010-11-21
ZA200905145B (en) 2010-04-28
BRPI0902387A2 (pt) 2011-02-01
JP2010270100A (ja) 2010-12-02
RU2009127394A (ru) 2011-01-27
TW201041878A (en) 2010-12-01
KR20100126146A (ko) 2010-12-01
CN101890171A (zh) 2010-11-24
EP2253627A1 (en) 2010-11-24
AU2009202887A1 (en) 2010-12-09
IL199883A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
ZA201504665B (en) Processes and apparatus for producing nanocellulose, and compositions and products produced therefrom
JO3674B1 (ar) مشتقات ثنائية الحلقة جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
CL2015001437A1 (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
GB201209613D0 (en) New compounds
BR112015001782A2 (pt) método para produzir uma composição para o tratamento de um dente lesionado
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
DOP2015000215A (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
BR112015028565A2 (pt) Processos de pré-condicionamento de material e de produção de um produto
CY1118198T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
AR072561A1 (es) Complejo de inclusion de clorhidrato de raloxifeno y b- ciclodextrina
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
AR128635A2 (es) Formulación de flumioxazina, composición herbicida que lo comprende y método para producir un herbicida
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
IN2013MU02576A (es)
CR20150545A (es) Agentes quelantes de precursores de producto final de glicación avanzada (age)

Legal Events

Date Code Title Description
FB Suspension of granting procedure